Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (111-120 of 186) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|December 8, 2015
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trialShuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi, et al.
Esophagus : Official Journal of the Japan Esophageal Society|April 20, 2026
Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab responseYuho Ebata, Eiji Oki, Qingjiang Hu, et al.
Med (New York, N.Y.)|June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRCHideaki Bando, Daisuke Kotani, Hironaga Satake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM StudyYoshinori Kagawa, Elena Elez, Jesús García-Foncillas, et al.
JCO Precision Oncology|March 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA SubstudyYuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, et al.
Nature Communications|July 13, 2024
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudyHiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, et al.
ESMO Open|December 5, 2019
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with <i>BRAF</i> V600E mutant metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, et al.
JCO Precision Oncology|January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH TrialMitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
International Journal of Clinical Oncology|June 9, 2026
A multicenter survey on BRAF screening for the implementation of perioperative cancer genomic medicine for resectable colorectal oligometastasesShin Kobayashi, Nobuhisa Matsuhashi, Yusuke Suwa, et al.
Cancer Medicine|August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit studySatoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Pageof 19

Showing results (111-120 of 186) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|December 8, 2015
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trialShuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi, et al.
Esophagus : Official Journal of the Japan Esophageal Society|April 20, 2026
Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab responseYuho Ebata, Eiji Oki, Qingjiang Hu, et al.
Med (New York, N.Y.)|June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRCHideaki Bando, Daisuke Kotani, Hironaga Satake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM StudyYoshinori Kagawa, Elena Elez, Jesús García-Foncillas, et al.
JCO Precision Oncology|March 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA SubstudyYuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, et al.
Nature Communications|July 13, 2024
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudyHiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, et al.
ESMO Open|December 5, 2019
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with <i>BRAF</i> V600E mutant metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, et al.
JCO Precision Oncology|January 17, 2025
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH TrialMitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, et al.
International Journal of Clinical Oncology|June 9, 2026
A multicenter survey on BRAF screening for the implementation of perioperative cancer genomic medicine for resectable colorectal oligometastasesShin Kobayashi, Nobuhisa Matsuhashi, Yusuke Suwa, et al.
Cancer Medicine|August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit studySatoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Pageof 19